AGP Executive Report
Last update: 9 hours agoCancer Advances: Retlirafusp alfa improved overall survival in a phase 3 trial for HER2-negative gastric cancer, while the FDA expanded ANKTIVA’s approval for papillary bladder cancer. AI Drug Development: AstraZeneca and insitro signed a deal worth up to $1.5 billion to discover treatments for MASH and cardiomyopathies, reflecting pharma’s growing investment in AI research. Device Safety: The FDA flagged an Edwards heart-valve delivery system after reports of a death and an injury. Drug Access: India is tightening patent rules to curb evergreening and speed access to generic medicines. Public Health: A large study linked short-term PM2.5 exposure to higher hospitalisation risk for up to three weeks, extending concerns beyond respiratory illness. Alzheimer’s Research: Many willing volunteers are screened out of trials; the World Alzheimer Report says 44% of applicants for mild Alzheimer’s trials and 88% for preclinical trials do not qualify.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[ The Unique Considerations Mid-Sized Pharma Companies Face When Making MFN Deals]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/29479793-950169651-30e8073b2dc0176507c7f29f8a3546cb19aa3b7a-1280x720-200x113.jpeg)
